A case of large-cell neuroendocrine carcinoma harboring an EML4-ALK rearrangement with resistance to the ALK inhibitor crizotinib.
Departments of *Internal Medicine, †Laboratory Medicine and Pathology, and ‡Surgery, National Hospital Organization Kinki-chuo Chest Medical Center, Osaka, Japan.
Naoki
N
Omachi
Shigeki
S
Shimizu
Tomoya
T
Kawaguchi
Kenji
K
Tezuka
Masaki
M
Kanazu
Akihiro
A
Tamiya
Kazuhiro
K
Asami
Kyoichi
K
Okishio
Masanori
M
Kitaichi
Shinji
S
Atagi
D000328:Adult; D001943:Breast Neoplasms / Q000235:genetics* / Q000556:secondary / Q000601:surgery; D018287:Carcinoma, Large Cell / Q000188:drug therapy / Q000235:genetics* / Q000556:secondary; D018278:Carcinoma, Neuroendocrine / Q000188:drug therapy / Q000235:genetics* / Q000556:secondary; D000077547:Crizotinib; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005260:Female; D015321:Gene Rearrangement; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D008558:Melphalan / Q000627:therapeutic use; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D011720:Pyrazoles / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000556:secondary
C522504:EML4-ALK fusion protein, human; D007074:Immunoglobulin G; D015514:Oncogene Proteins, Fusion; D011720:Pyrazoles; D011725:Pyridines; C051713:antineoplastic agent K 18; D000077547:Crizotinib; D008558:Melphalan